Abstract
In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Current Pharmaceutical Design
Title: Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Volume: 16 Issue: 35
Author(s): Carine Munaut, Alain C. Colige and Charles A. Lambert
Affiliation:
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Abstract: In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Export Options
About this article
Cite this article as:
Munaut Carine, C. Colige Alain and A. Lambert Charles, Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455012
DOI https://dx.doi.org/10.2174/138161210794455012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry The Emerging Pharmacology of TRPM8 Channels: Hidden Therapeutic Potential Underneath a Cold Surface
Current Pharmaceutical Biotechnology Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Evaluation of Cytotoxic, COX Inhibitory, and Antimicrobial Activities of Novel Isoxazole-carboxamide Derivatives
Letters in Drug Design & Discovery Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Scintigraphic Imaging of Inflammatory Processes
Medicinal Chemistry Reviews - Online (Discontinued) Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Current Hydrogel Solutions for Repairing and Regeneration of Complex Tissues
Current Medicinal Chemistry Retinoids in Clinical Use
Medicinal Chemistry Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Isolation of a New Trypsin Inhibitor from the Faba Bean (Vicia faba cv. Giza 843) with Potential Medicinal Applications
Protein & Peptide Letters Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Role of Exosomes in Photodynamic Anticancer Therapy
Current Medicinal Chemistry Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Potential of Unengineered and Engineered Wharton’s Jelly Mesenchymal Stem Cells as Cancer Inhibitor Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Total Synthesis, Mechanism of Action, and Antitumor Efficacy of Camptothecin and Some of its Analogues
Anti-Cancer Agents in Medicinal Chemistry Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets